Center for Immunotherapy and Cell-Based Technologies
Novosibirsk — Kaliningrad — Moscow — Irkutsk
Main →
Melanoma
Xenovaccinotherapy for cancer
http://www.medicalnewstoday.com/rss/cancer-oncology.xmlhttp://www.medicalnewstoday.com/rss/immune_system.xmlhttp://www.medicalnewstoday.com/rss/multiple_sclerosis.xmlhttp://www.medicalnewstoday.com/rss/stem_cell_research.xml
10.02.2012
Fasting was as effective as chemotherapy in delaying growth of specific tumors in mice and boosted the effectiveness of chemotherapy on melanoma, gli...
21.01.2012
A collaboration between a cancer biologist from the University of Milano and 2 physicists has shown that cell senescence occurs spontaneously in mela...
19.01.2012
According to a study published in the New England Journal of Medicine, researchers at The Institute of Cancer Research (ICR) have demonstrated how to...
08.01.2012
According to an investigation published in Cancer Prevention Research, a journal of the American Association for Cancer Research, antiestrogen supplem...
06.01.2012
According to an investigation published in Cancer Prevention Research, a journal of the American Association for Cancer Research, antiestrogen supplem...
05.01.2012
A study published in the December issue of the Archives of Dermatology, one of the JAMA/Archives journals reveals that, cancer survivors have a higher...
16.12.2011
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) announced today its recommendation that Zelboraf (vemurafenib)...
09.12.2011
Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt ...
29.11.2011
Researchers from UCLA's cancer and stem cell centers have demonstrated for the first time that blood stem cells can be engineered to create cancer-ki...
03.11.2011
Good news for anyone worried about skin cancer with the FDA approving Melafind, which the manufacturers describe as a groundbreaking technology for de...
Immunotherapy for cancer
An active specific immunotherapy (vaccinotherapy) is a strategy using tumor-associated antigens for including antitumor immune responses. The small structural distinctions of the xenogenic tumor-associated antigens from their human analogues render these antigens highly immunogenic and capable of including immune-mediated, antitumor responses in a patient not only at early, but also at advanced stages of disease, when tumor-derived immunosuppression is significant. Tumor-specfic immunotherapy is able to generate a selective and long-term antitumor effect. Such a therapy has no complications attributable to chemotherapy.
Xenovaccinotherapy for cancer